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Abstract 
Adult T-cell leukemia (ATL) is an aggressive disease characterized by visceral invasion, 
and ATL regulates matrix metalloproteinase (MMP) activities of the endothelial cells.  
The controlling system of MMP activities in ATL is regulated by various factors such 
as Emmprin and tissue inhibitor of MMP.  In this study, we demonstrated that Testican 
3 expression in ATL decreased the activity of MMP.  Furthermore, we showed that the 
expression of Testican 3 was regulated by activating transcriptional factor 3 in human 
T-lymphotropic virus type I-related cell lines.  Thus, Testican 3 is a novel regulator to 
reduce the activity of MMP in ATL. 
 
Keywords adult T-cell leukemia, human T-lymphotropic virus type I, activating 
transcriptional factor 3, Testican 3 
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Introduction 
Vascular infiltration of tumor cells through the endothelial cells is a critical step of 
cancer invasion and metastasis, which is an important prognostic factor of malignant 
diseases.  In this process of neoplasm infiltration, production of matrix 
metalloproteinases (MMPs) from vascular endothelial cells is increased [1].  In human 
T-lymphotropic virus type I (HTLV-I)-related diseases, malignant cells express 
MMP-13 activating protein, Emmprin, which activates MMP-2 [2].  Co-culture of 
fibrocytes with HTLV-I related cell line MT-2 showed high expression of MMP-2 when 
MT-2/fibrocyte ratio was 0.1, whereas the activity of MMP-2 was decreased when 
MT-2/fibrocyte ratio was 1.0 [2].  As MT-2 increases MMPs activity of fibrocytes, 
high MT-2/fibrocyte ratio should result in high MMPs secretion.  Therefore, we 
hypothesized that MT-2 secretes not only MMP activating Emmprin but also MMP 
inhibiting factors.  To evaluate the difference in MMP activity between co-cultured 
human aortic endothelial cells (HAECs) with MT-2 and adult T-cell leukemia (ATL) 
derived cell line MT-1, cDNA subtraction analysis was performed using MT-2 and 
MT-1. 
 
Materials and Methods 
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Cells Culture 
HTLV-I-transformed cell lines MT-2 and MT-4, ATL-derived cell lines MT-1 and 
ATL-1K, and HAECs (KURABO, Japan) were cultured in conditions of RPMI medium 
1640 (Invitrogen, USA) supplemented with 10% fetal bovine serum (FBS) (Invitrogen, 
USA) at 37°C in as humidified atmosphere containing 5% CO2. 
 
Gelatin zymography 
HAECs (1 x 106) were seeded on 6-well culture dish and cultured for 2 days.  Culture 
media were removed before co-culture with the HTLV-I related cell lines.  HTLV-I 
related cell lines (1 x 105 or 1 x 106) were added and cultured for 2 days with FBS-free 
RPMI1640 culture media.  Supernatants were collected and used for zymography 
analysis [2].  The gelatinolytic activity of MMP-2 and MMP-9 in the co-cultured 
supernatants were evaluated using gelatin zymography by the methods of supplier 
(Cosmo bio, Japan).  In brief, after 30 hour-incubation at 37 °C in developing buffer, 
the gel was stained with 0.1 % Coomassie Brilliant Blue R250.  For analyses of 
gelatinolytic activity of MMP-2 and MMP-9, gels were scanned and were imported into 
Adobe Photoshop software (v. 7.0, Adobe System). 
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RNA isolation and cDNA subtraction 
Total cellular RNA was isolated with the TRIzol reagent (Invitrogen, USA), and DNA 
contamination was removed by DNase treatment.  cDNAs of MT-1 and MT-2 were 
formed by SMART PCR cDNA Synthesis Kit (Clontech, Japan) and then cDNA 
subtraction was performed by PCR-Select cDNA Subtraction Kit (Clontech, Japan) 
according to the methods of supplier [4].  After cDNA subtraction, PCR product was 
cloned in E. coli DH5-α with pCR2.1-TOPO vector using TOPO TA cloning kit 
(Invitrogen, USA).  Plasmid DNA from DH5-α was isolated and sequencing reaction 
was carried out by Big Dye Terminators v1.1 Cycle Sequencing Kit (Applied 
Biosystems, UK), and then analyzed by ABI 310 Genetic Analyzer (Applied 
Biosystems, UK).  Searches with the BLAST program 
(http://www.ncbi.nlm.nih.gov/blast/) were conducted for all sequences to analyze 
unknown sequences detected with the cDNA subtraction method. 
 
Reverse-transcription (RT)-PCR 
Peripheral blood mononuclear cells (PBMCs) of a healthy donor and leukemia cells of 8 
patients with acute leukemia were prepared by Lymphoprep (Daiichi Pure Chemicals, 
Japan) and total RNAs were extracted.  Two samples of non-Hodgkin lymphoma 
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(NHL) and 5 samples of ATL were collected by biopsy or necropsy from pathological 
lymph nodes, and total RNAs were extracted from these samples.  Informed consent 
was obtained from all patients and healthy donor.  cDNA was synthesized from 400 ng 
of total cellular RNA with High Capacity cDNA Reverse Transcription Kit (Applied 
Biosystems, Japan).  The cDNA was then amplified by PCR using Blend Taq Plus 
DNA polymerase (TOYOBO, Japan).  Amplification of the housekeeping gene 
ribosomal RNA L7a was used to verify RNA quality and RT-PCR techniques.  
Expression of L7a, Testican 3 (GenBank accession number AJ001454; Maurer, 1997) 
and ATF3 were examined by RT-PCR as described previously [5] using the following 
PCR primers; L7a forward primer, 5'- ATGGGTCAGAAGGATTCCTA -3'; L7a 
reverse primer, 5'- CGTCACACTTCATGATGGA -3'; Testican 3 forward primer, 5'- 
CTCAAGATTCTCAGACTGCA -3'; Testican 3 reverse primer, 5'- 
GAGCTCTGACTGGTCCA -3'; ATF3 forward primer, 5'- 
CTCCTGGGTCACTGGTGTTT -3', ATF3 reverse primer, 5'- 
GTCGCCTCTTTTTCCTTCA -3'.  Products size were 204 bp for L7a, 494 bp for 
Testican 3 and 204 bp for ATF3.  Cycling condition was followed by 30 cycles 
consisting 94°C for 30 s, 57°C for 30 s and 72°C for 1.5 min.  PCR products were 
electrophoresed in 2% agarose gels and visualized with ethidium bromide staining. 
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Western blotting of ATF3 and Testican 3 
Protein extracts from MT-2 and 5 ATL patients were electrophoresed on SDS-12% 
polyacrilamide gel (SDS-12% PAGE) and blotted onto Hybond enhanced 
chemiluminescence nitrocellulose membranes (Amersham Pharmacia Biotech, USA).  
The blot was subsequently incubated with a rabbit anti-human-ATF3 antibody (Santa 
Cruz Biotechnology Inc, USA: dilution 1:200) and anti-rabbit IgG antibody-HRP (Santa 
Cruz Biotechnology Inc, USA: dilution 1:200).  The blots were performed by 
chemiluminescence with ECL-Plus Western Blotting Detection System (Amersham 
Pharmacia Biotech, USA).  For a standard control, anti-human-GAPDH antibody 
(Santa Cruz Biotechnology Inc, USA: dilution 1:200) was used.  To detect Testican 3, 
goat anti-human-Testican 3 antibody (Santa Cruz Biotechnology Inc, USA: dilution 
1:200) was used for the first antibody reaction, and donkey anti-goat IgG antibody-HRP 
was used for the second antibody (Santa Cruz Biotechnology Inc, USA: dilution 
1:2000). 
 
Target gene silencing by short interfering RNA (siRNA) 
Stealth siRNA (Invitrogen, USA) targeting ATF3-HSS100777 was used for silencing 
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the gene [6].  siRNA sequence for silencing ATF3 is double strand RNA, 
AAUCUUAUUUCUUUCUCGUCGCCUC, and its complementary sequence.  This 
double-stranded siRNA was transfected into MT-2 cells using Lipofectamine 2000 
(Invitrogen; USA).  In brief; 100 pmol of these double-stranded siRNA and 50 µl of 
Lipofectamine 2000 in 500 µl of Opti-MEM I Reduced-Serum medium (Invitrogen; 
USA) were mixed and incubated at room temperature for 20 min.  The mixture was 
added to 2 ml of pre-culture Opti-MEM I serum-reduced medium with 1 x 106 MT-2 
cells, and incubated at 37°C for 48 hours.  Total RNAs were analyzed by RT-PCR. 
 
Induction of ATF3 in HTLV-I-related cell lines 
Anisomycin is a strong inducer of ATF3 to activate p38 or c-Jun N-terminal kinase 
pathway [7].  To induce ATF3, anisomycin (Calbiochem, USA) was added to the 
culture media of MT-1, MT-2, ATL-1K and MT-4 (final concentration 50 ng/ml).  
After 3 hours incubation, total RNA was extracted and RT-PCR was used for the 
expression of ATF3 and Testican 3. 
 
Results 
Gelatin zymography analysis of co-cultured HAEC with HTLV-I related cell lines 
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MT-1 (1 x 105) and HAECs (1 x 106), MT-1 (1 x 106) and HAECs (1 x 106), MT-2 (1 x 
105) and HAEC (1 x 106), and MT-2 (1 x 106) and HAEC (1 x 106) were co-cultured for 
2 days, and supernatants were collected.  Gelatin zymography analyses were 
performed for these supernatants.  Figure 1 shows 72 kDa band of pro-MMP-2 and 62 
kDa band of active form of MMP-2 by zymogram.  When HAEC was co-cultured with 
MT-1, zymogram showed high activity of MMP-2 at MT-1/HAEC ratio=1.0.  
However, when HAEC was co-cultured with MT-2, MMP-2 activity became lower by 
changing MT-2/HAECs ratio 0.1 to 1.0.  Considering that MT-2 secreted MMP-13 
activating Emmprin by contacting the endothelial cells, these results suggest that MT-2 
also secreted some factors that inhibited MMPs activation. 
 
cDNA subtraction of MT-1 and MT-2 
After 2 days of FBS-free RPMI1640 culture, total RNA was extracted from MT-1 and 
MT-2.  cDNA subtraction of these HTLV-I-related cell lines revealed sequences with 
different expression levels and those were analyzed by BLAST search 
(http://www.ncbi.nlm.nih.gov/blast/).  Dominant sequence of MT-1 was CD99 mRNA 
and dominant sequences of MT-2 were ATF3 mRNA, Testican 3 mRNA and CD9 
mRNA.  RT-PCR was performed for ATF3 and Testican 3.  MT-2 showed high 
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expression of Testican 3 and ATF3, but MT-1 showed only weak ATF3 expression (Fig. 
2). 
 
Analysis of ATF3 and Testican 3 expression 
To detect ATF3 and Testican 3 expressions in hematological malignancies, RT-PCR 
was performed in 17 cell lines and 15 clinical samples of hematological malignancies.  
Figure 3A shows ATF3 and Testican 3 mRNA expression in cell lines of hematological 
malignancies; chronic myelogenous leukemia-derived cell lines (CML-C-2 and K562), 
acute myelogenous leukemia-derived cell lines (PL21 and NM4), Hodgkin 
lymphoma-derived cell line (HD70), B-cell lymphoma-derived cell line (SP49), B-cell 
acute lymphocytic leukemia-derived cell lines (BALL, NALL and PALL), T-cell acute 
lymphocytic leukemia-derived cell lines (TALL1 and TALL2), T-cell lymphoblastic 
cell lines (CEM and Jurkat), ATL-derived cell line (MT-1), HTLV-I-transformed cell 
line (MT-2), ATL-derived cell line (ATL-1K), and HTLV-I-transformed cell line 
(MT-4).  MT-2 showed expression of Testican 3 mRNA and HTLV-I related cell lines 
showed high expression of ATF3.  Figure 3B shows ATF3 or Testican 3 mRNA 
expression in clinical samples of hematological malignancies.  RT-PCR revealed 
ATF3 and Testican 3 amplification from 4 AML, 1 CML blast crisis, 1 chronic 
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lymphocytic leukemia, 2 ALL, lymph nodes of 2 NHL, and lymph nodes of 5 ATL.  
Healthy human PBMCs was used for normal control.  Five ATL samples showed 
highly expressed ATF3 and Testican 3 by RT-PCR.  Highly expressed ATF3 and 
Testican 3 were observed in 5 lymph nodes of ATL patients by western blotting (Fig. 
3C).  These results indicate that ATF3 expression was related to Testican 3 expression 
in ATL lymph nodes. 
 
ATF3 silencing with siRNA treatment 
To evaluate the relation between the expression of ATF3 and Testican 3, ATF3 
silencing was performed by Stealth siRNA ATF3-HSS100777.  RT-PCR of ATF3 and 
Testican 3 were performed 48 hours after adding siRNA.  siRNA effectively inhibited 
the expression of ATF3 (Fig. 4.A).  The expression of Testican 3 was also reduced in 
ATF3 silenced MT-2.  Co-cultured supernatant of 1 x 106 HAECs with 1 x 105 ATF3 
silenced MT-2 showed high MMP-2 activities by gelatin zymography analysis (Fig. 
4B). 
 
ATF3 induction for HTLV-I related cell lines 
ATF3 is a stress induced transcriptional factor and is related with various mitogen 
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activated protein kinase (MAPK) pathways.  Anisomycin is a strong stimulator of 
MAPK that induces ATF3.  Anisomycin (final concentration; 100 pmol) was added to 
MT-1, MT-2, ATL-1K and MT-4 in FBS-free RPMI1640.  After 3 hours, RNAs were 
extracted, and RT-PCR for ATF3 and Testican 3 were performed (Fig. 5).  Not only 
MT-2, but also MT-1 and MT-4 showed expression of ATF3 and Testican 3 by adding 
anisomycin.  These results indicate that ATF3 induction might be related to Testican 3 
expression. 
 
Discussion 
HTLV-I is the causative agent of ATL [8] and tropical spastic 
paraparesis/HTLV-I-associated myelopathy (TSP/HAM) [9].  In the early 1980s, 
Miyoshi et al. established 2 HTLV-I-infected cell lines, one was MT-1 of ATL cell 
origin [10] and another was MT-2 of HTLV-I-transformed cell line [11].  ATL cells 
influence MMP activities of the endothelial cells by cell-to-cell contact, and infiltrate by 
destroying basement membrane and tight junction [12].  The infiltration system must 
possess regulation mechanism that contains not only MMPs activation to break the 
basement membrane, but also MMP activities inhibition to retain malignant cells in the 
tissue.  Among the cell lines of hematological malignancies, RT-PCR revealed that 
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Testican 3 expression was detected only in MT-2.  In the clinical samples of 
hematological malignancies, Testican 3 was expressed in ATL patients, but not in other 
hematological malignancies.  This is the first report of Testican 3 expression in ATL. 
Testican 3 is one of the BM-40 matrix proteins mainly expressed in the brain [3].  
Testican 3 is an MMPs inhibitor because glioma cells showed metastasis in the absence 
of Testican 3 expression [3].  Testican 3 inhibits the activation of MMPs by 
interrupting membranous type MMP [3].  In contrast, tissue inhibitor of 
metalloproteinase (TIMP) inhibits MMPs by interrupting MMPs-substrates interaction 
[13].  Moreover, many invasive neoplasm express membranous type MMP activating 
Emmprin [2].  We detected high expression of Emmprin in all the cell lines and 
clinical samples of hematological malignancies by RT-PCR (data not shown).  These 
MMP regulating factors expressed in ATL cells might be related to each other and act to 
retain or invade local lesion of ATL.  Considering that HTLV-I-infected cells of 
TSP/HAM remains in the central nervous system (CNS) for long time, Testican 3 
expression in CNS could also be related to the progression of TSP/HAM.  Although 
the functions of Testican 3 in ATL are not clear, Testican 3 may reduce infiltration of 
ATL cells by controlling MMPs activities.  For ATL cells, to remain in the lymph 
nodes or subcutaneous lesions, Testican 3 must be an important factor for 
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tumorigenesis. 
cDNA subtraction analysis also detected the difference of ATF3 expression between 
MT-1 and MT-2.  MT-2 showed high expression of ATF3, but MT-1 showed weak 
expression of ATF3.  Interestingly, western blot analysis in ATL patients showed that 
the intensity pattern of ATF3 and that of Testican 3 was proportionally, which indicate 
that ATF3 regulated the expression of Testican 3.  Stress induced transcriptional factor 
ATF3 acts as a reducer of transcription [14].  There are many reports indicating that 
ATF3 expressions are influenced by MAPK pathway [7].  This is supported by the 
following results: p38 MAPK mainly influences expression of ATF3and results in 
apoptotic changes of mouse embryonic fibroblasts [7]; ATF3 forms heterodimer with 
other transcriptional factors and inhibits transcriptional activities of c-Jun [6].  Among 
hematological malignancies, Hodgkin lymphoma cells expressed high ATF3 [15].  Our 
study showed that ATF3 expression and Testican 3 expression was related in ATL.  
However, Testican 3 was not expressed in the clinical samples and cell lines of 
hematological malignancies except ATL or HTLV-I related cell lines.  The existence 
of Tax and HTLV-I b-zip factor (HBZ) in HTLV-I-related disease could be unique 
additional factors not observed in other hematological malignancies.  These are 
supported by the following results: Tax enhances the transcriptional activity of ATF3 
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[16] and HBZ reduces transcriptional activity of other transcriptional factors [17].  In 
our study, MT-2 showed no expression of Testican 3 when ATF3 was silenced, but 
MT-1 and MT-4 showed high expression of Testican 3 when ATF3 was induced by 
anisomycin.  These results indicate that ATF3 regulates Testican 3 expression and is 
related to the tumourigenesis of ATL.  Considering that ATF3 was highly induced by 
ultra-violet [18], Testican 3 regulated by ATF3 could retain the local growth of ATL 
cells in the subcutaneous lesion by inhibiting activities of MMP. 
In conclusion, we provided the first evidence that Testican 3 was highly expressed in 
ATL, and Testican 3 regulated by ATF3 reduced MMP-2 activity in HTLV-I related 
cell lines.  Thus, Testican 3 expression regulated by ATF3 could be related to the 
tumorigenesis of HTLV-I-associated diseases. 
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Figure Legends 
Figure 1 
Stimulation of MMP-2 gelatinolytic activity in co-cultured HAECs with HTLV-I 
related cell lines.  Gelatin zymography was performed with culture media collected 
from 2 days of culture.  The numbers under the zymogram indicate the cell number of 
HTLV-I related cell lines and HAECs used in co-cultures.  Bands at 72 and 62 kDa 
correspond to pro- and activated forms of MMP-2 respectively. 
 
Figure 2 
RT-PCR for mRNA expression of ATF3 and Testican 3 in MT-1 and MT-2 cells.  A 
housekeeping gene ribosomal RNA L7a was used to verify RNA quality and RT-PCR 
techniques.   
 
Figure 3 
(A) ATF3 and Testican 3 expression in cell lines of various hematological 
malignancies.   
(B) ATF3 and Testican 3 expression in clinical samples of hematological malignancies.   
(C) Western blotting for ATF3 and Testican 3 in ATL. 
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Figure 4 
(A) ATF3 silencing in MT-2.  Wild type MT-2, MT-2 with ATF3 siRNA and MT-2 
with control siRNA were cultured for 48 hours after treatment by siRNA.  Amplified 
bands are for ATF3 and Testican 3, respectively.  Lane 1: wild type MT-2, Lane 2: 
MT-2 with ATF3 siRNA, Lane 3: MT-2 with control siRNA 
(B) Gelatin zymography analysis of HAECs co-cultured with ATF3 silenced MT-2.  
Lane 1: wild type MT-2 (1 x 106), lane 2: HAECs (1 x 106), lane 3: HAECs (1 x 106) 
with MT-2(1 x 105), lane 4: HAECs (1 x 106) with ATF3 silenced MT-2 (1 x 105), lane 
5: HAECs (1 x 106) with control siRNA added MT-2 (1 x 105).  Bands at 72 and 62 
kDa correspond to pro- and activated forms of MMP-2 respectively. 
Figure 5 
Induction of ATF3 in HTLV-I related cell line.  RT-PCR of ATF3 and Testican 3 was 
performed after anisomycin treatment for MT-1, MT-2, ATL-1K and MT-4.  
Anisomycin added MT-2 showed higher expression of Testican 3.  MT-1 and MT-4 
also showed expression of Testican 3 by adding anisomycin. 
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